<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985348</url>
  </required_header>
  <id_info>
    <org_study_id>N01339</org_study_id>
    <nct_id>NCT00985348</nct_id>
  </id_info>
  <brief_title>Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)</brief_title>
  <official_title>Randomized, Monocenter, Open Label, Two-way Cross-over, Single Dose Bioequivalence Study of Two Oral Formulations of Levetiracetam in Healthy Male &amp; Female Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the bioequivalence of a Levetiracetam dry syrup (50% (500mg/1000mg)) versus
      Levetiracetam 500 mg oral tablet, used as reference, after single dose administration in
      healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum plasma concentration) of Levetiracetam.</measure>
    <time_frame>36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t) (Area under the plasma concentration vs. time curve observed from time 0 h up to the last measurable data point) of Levetiracetam</measure>
    <time_frame>36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Area under the curve extrapolated to infinity) of Levetiracetam</measure>
    <time_frame>36 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax (time of maximum plasma concentration) of Levetiracetam</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (Terminal elimination rate constant) of Levetiracetam</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (Terminal elimination half-life) of Levetiracetam</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT (Mean Residence Time) of Levetiracetam</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (Apparent total body clearance) of Levetiracetam</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (Apparent volume of distribution) of Levetiracetam</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment 1/Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2/Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam (Keppra)</intervention_name>
    <description>Test Drug :
Levetiracetam dry syrup
Reference Drug :
500 mg oral tablets of Levetiracetam. Frequency: Single Dose</description>
    <arm_group_label>Treatment 1/Treatment 2</arm_group_label>
    <arm_group_label>Treatment 2/Treatment 1</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent dated and signed by subject.

          -  Healthy male or female Japanese volunteer from the first generation, living outside of
             Japan for less than 10 years, age range 20 to 55 years inclusive.

          -  Body Mass Index (BMI) between 18.0 and 28.0 kg/m² inclusive.

        Exclusion Criteria:

          -  Pregnant, lactating or sexually active women with childbearing potential who are not
             using a medically accepted birth control method.

          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             endocrinological, neurological, psychiatric disorders capable of altering the
             absorption, metabolism or elimination of drugs, or of constituting a risk factor when
             taking the study medication.

          -  History of drug addiction or presence of drug addiction (positive drug screen) or
             excessive use of alcohol (weekly intake in excess of 21 units alcohol for male and 14
             units alcohol for female; one unit alcohol equals one glass of beer or lager, a glass
             of wine or a measure of spirits), of psychological or other emotional problems that
             are likely to invalidate informed consent, or limit the ability of the subject to
             comply with the protocol requirements.

          -  Heavy caffeine drinker (drinking &gt;5 cups of coffee or equivalent, approximately 500mg
             of caffeine per day).

          -  Smokers of more than 10 cigarettes per day or smokers not willing to abstain from
             smoking while in the clinic for each period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levetiracetam</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

